

NEXTGEN BIOSCIENCE INC.
Form NT 10-K
December 31, 2007

**UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION**

Washington, D.C. 20549

FORM 12b-25

NOTIFICATION OF LATE FILING

(Check one):

OMB APPROVAL
OMB Number:
3235-0058
Expires: April 30,
2009
Estimated average
burden
hours per response
.... 2.50

SEC FILE
NUMBER
000-51935

Form 10-K Form 20-F Form 11-K
 Form 10-Q Form 10-D Form N-SAR Form N-CSR

For Period Ended: September 30, 2007

- Transition Report on Form 10-K
- Transition Report on Form 20-F
- Transition Report on Form 11-K
- Transition Report on Form 10-Q
- Transition Report on Form N-SAR

For the Transition Period Ended:

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I REGISTRANT INFORMATION

NEXTGEN BIOSCIENCE INC.

Full Name of Registrant

N/A

Former Name if Applicable

Edgar Filing: NEXTGEN BIOSCIENCE INC. - Form NT 10-K

46 Aldgate High Street

Address of Principal Executive Office (*Street and Number*)

London, England EC3N 1AL

City, State and Zip Code

PART II RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

- (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
- (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
- (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

The preparation of the Company's Annual Report on Form 10-KSB and the accompanying audited consolidated financial statements for the year ended September 30, 2007 were not completed in sufficient time to enable the Company to complete the filing of the Form 10-KSB within the prescribed period. The Company anticipates that the Form 10-KSB will be filed on or before the fifteenth calendar day following the prescribed due date.

PART IV OTHER INFORMATION

- (1) Name and telephone number of person to contact in regard to this notification

Konstantinos Kardiasmenos
(Name)

+44 (0)
(Area Code)

207-744-7711
(Telephone Number)

- (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

Yes [] No

- (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

[] Yes No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

NEXTGEN BIOSCIENCE INC.

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Edgar Filing: NEXTGEN BIOSCIENCE INC. - Form NT 10-K

Date: December 31, 2007

By: */s/ Konstantinos Kardiasmenos*

Konstantinos Kardiasmenos

Title: Chief Executive Office and Chief Financial Officer
